Internal validation supports the robustness of findings within this single-center, 40-patient cohort.<h4>Conclusions</h4>A plasma metabolite-based risk score derived from six biomarkers independently predicts survival in advanced GC treated with PD-1-based immunotherapy and offers a practical tool for individualized prognosis. Here, PDCD1 is linked to gastric cancer.